Asset
VALBENAZINE
NEUROCRINE BIOSCIENCES INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (27)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02274558 | phase3 | completed | 2014-10-01 | 2015-09-01 | Neurocrine Biosciences | A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia |
| NCT07105111 | phase4 | recruiting | 2025-08-29 | 2028-06-01 | Neurocrine Biosciences | A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor |
| NCT01267188 | phase2 | completed | 2011-01-01 | 2011-03-01 | Neurocrine Biosciences | Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia |
| NCT04102579 | phase3 | completed | 2019-11-13 | 2021-10-15 | Neurocrine Biosciences | Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease |
| NCT05110157 | phase3 | completed | 2021-11-29 | 2025-02-04 | Neurocrine Biosciences | Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia |
FDA applications (0)
This company has no applications containing this asset.